HUI LIU has litigated cases involving complex technological issues for over a decade. She has represented many international clients in patent infringement, patent licensing, and other contractual disputes before various U.S. district courts, New York state courts, and the U.S. International Trade Commission. She has also represented clients in international arbitration proceedings presenting complex commercial and contract law issues. Hui has handled many matters involving cutting-edge technologies including pharmaceutical development, metabolomics, semiconductor manufacturing, and plasma and liquid crystal displays. Hui also has extensive experience in Hatch-Waxman litigation and “soft-IP,” such as trademark and copyright, litigation and counseling.

Hui has assisted biotech companies, small startups, and universities in conducting pre-suit investigations (e.g., patent validity and infringement claim evaluations) and patent prosecution, and provided other intellectual property counseling services. 

Prior to becoming a lawyer, Hui was a Norman and Rosita Winston Postdoctoral Fellow at Rockefeller University in New York. An accomplished scientist, Hui has authored several research articles in prominent scientific journals in connection with her graduate and post-graduate work in microbiology and human genetics. 

Hui grew up in Hunan Province, mainland China, and is a native Chinese speaker.

Some of Hui’s representative matters include:

  • Consumer Electronics Litigation 
    • Member of trial team that successfully tried a high‐profile plasma display case in the Eastern District of Texas leading to a jury verdict of approximately $60 million.
    •  Member of core team that secured summary judgment of invalidity at the Southern District of New York for a major international manufacturer of LCD manufacturing tools, which led to favorable settlement for the client.   
  • International Arbitration
    • Member of core team that secured favorable settlement for a Chinese client through an arbitration proceeding involving a contract dispute against a U.S. manufacturer. 
    • Member of core team that secured favorable settlement for an European client on eve of arbitration hearing in a contract dispute against a major U.S. computer manufacturer.
    • Member of core team that secured a multi-million-dollar arbitration award for an international mining company that involved a mining contract dispute against a major U.S. contractor.
  • Hatch-Waxman Litigation
    • Member of core team that advised and represented a major U.S. generic drug manufacturer in connection with its filings of Abbreviated New Drug Applications.


  • Yale University (J.D., 2006)
  • University of Massachusetts Medical School (Ph.D., Biomedical Sciences, with a focus on molecular genetics and microbiology, 2000)
  • Peking University (B.Sc., Biochemistry, 1995)

Bar Memberships

  • Admitted in New York

Professional Activities and Honors

  • FINRA Dispute Resolution Arbitrator
  • New York-Metro Rising Stars List for Intellectual Property Litigation, Super Lawyers, 2014-2017
  • The American Arbitration Association Higginbotham Fellow, 2016   
  • Joint Annual Meeting, New York State Bar Dispute Resolution Section & Corporate Counsel Section (January 2015) (Co-Chair)
  • Fall Meeting, New York State Bar Dispute Resolution Section (Fall 2016) (Co-Chair)

Select Publications and Speaking Engagements

  • Patent Litigation, Chapter on “Case Strategy and Management,” Practicing Law Institute, Co-author, 2015-2018
  • “North Carolina Federal Court Rules on Impracticability of Arbitration Clause Mandating Completion 30 days Following Arbitrator Selection,” ABA Litigation Section ADR Committee Newsletter (Spring 2017)
  • Case Note, “Animal Sci. Prods. v. Hebei Welcome Pharm. Co. (2d Cir. 2016),” CPI Journal, Asia Column (December 2016)
  • Case Note, “McKenna Long & Aldridge, LLP v. Ironshore Specialty Ins. Co., Civ. Nos. 14-cv-6633 (KBF), 14-cv-6675 (KBF), 2015 U.S. Dist. LEXIS 3347 (S.D.N.Y. Jan. 2, 2015) – non-signatories may be compelled to arbitrate under direct-benefit estoppel or third-party beneficiary theories,” New York Dispute Resolution Lawyer (Fall 2015)
  • “Hatch-Waxman Litigation: The War Between Brand And Generic Goes To Court,” Sino-American Pharmaceutical Professionals Association-Greater Philadelphia, Special Webinar Session (April 2014)
  • “New Social Media: Trademark, Copyright, Privacy and Patent Perspectives,” The Association of the Bar of the City of New York, Women in Intellectual Property Series (February 2012) (panelist)
  • “Allele- and Tir-independent functions of intimin in diverse animal infection models,” Frontiers in Microbiology, 3:11 (2012)
  • “Altered brain micro RNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model,” Nature Genetics, 40, 751-760 (2008)
  • “Evidence that the gene encoding ZDHHC8 contributes to the risk of schizophrenia,” Nature Genetics, 36(7): 725-731 (2004)
  • “Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and in-creases susceptibility to schizophrenia,” Proceedings in National Academy of Sciences USA, 99(6), 3717-3722 (2002)